Trial | NCT02411344  Report issue

Title

Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy
PERtuzumab-trastuzumab Plus lEetrozoLe In Endocrine Sensitive Breast Cancer: a Phase II neoAdjuvant Study

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    pertuzumab ...

  • Study Participants

    64
The purpose of this study is to evaluate the activity of molecular response in endocrine sensitive breast cancer HER2+/HR+ patients treated with Pertuzumab-trastuzumab plus Ietrozole.
The purpose of this study is:

to evaluate the rate of pathologic complete response (pCR), as defined as complete disappearance of invasive tumor in breast and axillary nodes.
to estimate the percentage of clinical objective responses (cOR) (complete plus partial) in the breast, as assessed by ultrasonography (US)
to estimate the percentage of breast conservative surgery
to evaluate the safety profile
To perform correlative biomarker analyses
Study Started
Feb 28
2014
Primary Completion
Jan 12
2018
Study Completion
Jan 12
2018
Last Update
Sep 18
2018

Drug Pertuzumab

Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery).

  • Other names: Perjeta

Pertuzumab, Trastuzumab, Letrozole Experimental

Criteria 

Inclusion Criteria:

primary diagnosis of infiltrating breast cancer
HR positivity (ER ≥ 10% and/or PgR ≥10%) and HER2 positivity (IHC 3+ or FISH/CISH amplification), as assessed by local laboratory.
Stage II-IIIA
age >18 yrs
ECOG Performance Status 0-1

Postmenopausal status, defined by at least one of the following:

60 years of age; < 60 years of age and amenorrheic for >/=12 months prior to day 1 < 60 years of age, without a uterus, and luteinizing hormone (LH) and follicle stimulating hormone (FSH) values within postmenopausal range Prior bilateral oophorectomy Prior radiation castration with amenorrhea for at least 6 months

Cardiac ejection fraction within the institutional range of normal (as measured by echocardiogram or MUGA scan).
Normal organ and marrow function as defined below:

(leukocytes >=3000/mcL; absolute neutrophil count >=1,500/mcL; platelets >=100,000/mcL; total bilirubin within 1.25 x normal institutional limits (with the exception of Gilbert's syndrome); AST (SGOT)/ALT(SGPT) within 1.25 x institutional upper limit of normal creatinine within normal institutional limits

Availability of tumor tissue suitable for biological and molecular examination before starting primary treatment
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Stage IIIB, IIIC, and inflammatory breast cancer
Stage IV breast cancer
Prior treatment with chemotherapy, endocrine therapy or radiotherapy. Prior treatment with HER2 targeting therapies
LVEF below the ULN
Uncontrolled hypertension (systolic >150 mm Hg and/or diastolic >100 mm Hg) or clinically significant (i.e. active) cardiovascular disease: cerebrovascular accident (CVA)/stroke or myocardial infarction within 6 months prior to first study medication, unstable angina, congestive heart failure (CHF) of New York Heart Association (NYHA) grade II or higher, or serious cardiac arrhythmia requiring medication.
Received any investigational treatment within 4 weeks of study start.
Subjects with known infection with HIV, HBV, HCV
Known hypersensitivity to any of the study drugs or excipients.
Dyspnoea at rest or other disease requiring continuous oxygen therapy.
Psychiatric illness/social situations that would limit compliance with study requirements
Subjects assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
No Results Posted